Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Tirzepatide's dual GLP-1 and GIP receptor activity produces slightly greater weight loss (up to 22% in SURMOUNT trials) and superior metabolic improvements in glucose control
Cardiovascular risk If you have established cardiovascular disease with type 2 diabetes, it is suggested to talk to your healthcare professional before switching to Zepbound
Glucose-dependent insulinotropic polypeptide (GIP) receptor agonists In addition to being a GLP-1 RA, tirzepatide is also an agonist of GIP, a gut hormone that impacts glucose and fat metabolism.13 Its similar to GLP-1 in that it stimulates insulin secretion from the pancreas, and research shows that the two hormones work synergistically to increase weight loss
Cagrilintide is not approved for human use by the FDA or any regulatory agency
doi:10.1371/journal.pbio.3000410 38
Statistical analysis Results are presented as the mean SEM
